PLUS THERAPEUTICS, INC.
For the period ended Sep 30, 2025. Filed Oct 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 30, 2025
CNSY$0.57-11.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and par value data)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $13,289 | $76 |
| Investments | 3,312 | 3,530 |
| Grant receivable | — | 571 |
| Other current assets | 985 | 1,082 |
| Total current assets | 17,586 | 5,259 |
| Property and equipment, net | 273 | 448 |
| Operating lease right-of-use assets | 20 | 73 |
| Goodwill | 372 | 372 |
| Intangible assets, net | 374 | 469 |
| Other assets | 45 | 12 |
| Total assets | $18,670 | $6,633 |
| Liabilities and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $11,623 | $11,288 |
| Operating lease liability | 21 | 44 |
| Deferred grant liability | 1,972 | 927 |
| Line of credit | — | 3,292 |
| Total current liabilities | 13,616 | 15,551 |
| Noncurrent operating lease liability | — | 31 |
| Total liabilities | 13,616 | 15,582 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | — | — |
| Common stock, $0.001 par value; 2,000,000,000 shares authorized; 131,863,969 shares issued; and 131,605,544 shares outstanding as of September 30, 2025, and 100,000,00 shares authorized; 6,154,758 shares issued; and 5,896,333 shares outstanding as of December 31, 2024, respectively | 132 | 6 |
| Treasury stock (at cost), 258,425 shares as of September 30, 2025 and December 31, 2024, respectively | (500) | (500) |
| Additional paid-in capital | 515,574 | 485,024 |
| Accumulated deficit | (510,152) | (493,479) |
| Total stockholders’ equity (deficit) | 5,054 | (8,949) |
| Total liabilities and stockholders’ equity | $18,670 | $6,633 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.